Abstract
IJO is a rare condition of osteoporosis in childhood. The disease requires rapid growth to be clinically manifest and it occurs in adolescence or in early childhood. The pathogenesis is unknow. We examined 3 boys (FM, 2.3 yrs; DBM, 12.1 yrs, TM, 11.5 yrs) and 1 girl (GR, 12.6 yrs) with IJO. Ca, P, Mg were in normal range. Calciotropic hormones and therapy were as follows:
The therapy reduced incidences of fractures. After 6 mth (FM, TM, GR) and 1 yrs (FM, GR) of treatment, BMC was significantly (p < 0.01) increased. DBM showed a very slow increment of mineralization with significant recovery only 2.7 yrs after the first evaluation. No adverse effects of 1,25(OH)2D3 therapy were observed; CaU/CrU ratio remained in the normal range.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Saggese, G., Bertelloni, S. & Baroncelli, G. 1,25(OH)2D3 TREATMENT IN IDIOPATHIC JUVENILE OSTEOPOROSIS (IJO). Pediatr Res 20, 1207 (1986). https://doi.org/10.1203/00006450-198611000-00203
Issue Date:
DOI: https://doi.org/10.1203/00006450-198611000-00203